Dicerna Pharmaceuticals Inc to Post Q1 2019 Earnings of ($0.22) Per Share, B. Riley Forecasts (DRNA)

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) – Equities research analysts at B. Riley issued their Q1 2019 earnings per share (EPS) estimates for Dicerna Pharmaceuticals in a research note issued to investors on Tuesday, March 12th. B. Riley analyst M. Mamtani anticipates that the biopharmaceutical company will earn ($0.22) per share for the quarter. B. Riley currently has a “Buy” rating and a $24.00 target price on the stock. B. Riley also issued estimates for Dicerna Pharmaceuticals’ Q2 2019 earnings at ($0.23) EPS, Q3 2019 earnings at ($0.24) EPS, Q4 2019 earnings at ($0.26) EPS, FY2019 earnings at ($0.96) EPS, FY2020 earnings at ($1.48) EPS and FY2021 earnings at ($1.51) EPS.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The company had revenue of $1.54 million during the quarter, compared to analyst estimates of $8.38 million. Dicerna Pharmaceuticals had a negative return on equity of 65.91% and a negative net margin of 1,438.68%.

A number of other analysts have also weighed in on the stock. Chardan Capital raised shares of Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $18.00 price target for the company in a research note on Tuesday, January 22nd. BidaskClub lowered shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 12th. Leerink Swann initiated coverage on shares of Dicerna Pharmaceuticals in a research note on Tuesday, November 27th. They issued an “outperform” rating and a $24.00 price target for the company. ValuEngine lowered shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, February 25th. Finally, Zacks Investment Research lowered shares of Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $21.78.

Shares of NASDAQ:DRNA opened at $12.91 on Thursday. The company has a market capitalization of $772.23 million, a PE ratio of -10.76 and a beta of 2.40. Dicerna Pharmaceuticals has a twelve month low of $8.71 and a twelve month high of $17.98.

A number of hedge funds have recently added to or reduced their stakes in DRNA. Northern Trust Corp lifted its stake in Dicerna Pharmaceuticals by 719.5% during the second quarter. Northern Trust Corp now owns 486,668 shares of the biopharmaceutical company’s stock valued at $5,962,000 after purchasing an additional 427,284 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Dicerna Pharmaceuticals by 14.0% during the third quarter. JPMorgan Chase & Co. now owns 59,018 shares of the biopharmaceutical company’s stock valued at $900,000 after purchasing an additional 7,238 shares during the last quarter. Candriam Luxembourg S.C.A. acquired a new stake in Dicerna Pharmaceuticals during the third quarter valued at approximately $4,448,000. Swiss National Bank lifted its stake in Dicerna Pharmaceuticals by 21.1% during the third quarter. Swiss National Bank now owns 65,500 shares of the biopharmaceutical company’s stock valued at $1,000,000 after purchasing an additional 11,400 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its stake in Dicerna Pharmaceuticals by 137.3% during the third quarter. Alliancebernstein L.P. now owns 29,900 shares of the biopharmaceutical company’s stock valued at $456,000 after purchasing an additional 17,300 shares during the last quarter. 92.81% of the stock is owned by institutional investors and hedge funds.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

See Also: Fundamental Analysis – How It Helps Investors

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.